Spider Walkers: DNA Nanobots Indicate Cooperation Among Nanotechnology Researchers

Robert Enneser by Robert Ennesser

In 1676, Issac Newton wrote to rival researcher Robert Hooke, "[y]ou have added much in several ways, and . . . [i]f I have seen a little further it is by standing on the shoulders of giants."  Scientific and medical innovation occurs when the greatest numbers of researchers are able to use the best materials and methods available to develop new technologies and treatments.  Nanotechnology and genetics are two heavily patented areas with promising medical applications.  Unlike some current genetics companies that use patents to block researchers from studying their gene and developing new technologies, several recent nanotechnology studies are evidence that scholars across the country are working together and building off of each others' results. 

Two recent studies in Nature have illustrated how innovation builds from research findings of multiple groups.  Both studies make use of a technique known as "DNA origami"  DNA origami is the precise, nanoscale folding of a single strand of DNA on a synthetic scaffold.  DNA origami has been used to produce DNA in particular nanoscale structures, shapes, and patterns.  In the first study, a group of researchers led by biochemist Milan Stojanovic of Columbia University created molecular "robots" which move on top of a DNA origami pattern. Their robot "spider" is composed of a body and includes 3 legs which interact with a trail created by the researchers on the DNA origami pattern.  The body of the spider is made of a streptavidin molecule, a protein often used in biotechnology experiments which can be used to visualize nanoscale structures by attaching a molecule that fluoresces when excited by fluorescent light.  In the second study, a team of scientists led by Professor Nadrian Seeman at New York University created a DNA "assembly line" that can create 8 different arrangements of gold particles.  Seeman created a tiny robot "walker" composed of single-stranded DNA fragments with three "hands" that pick up and bind cargo and four "feet" that bind to a path on a DNA origami pattern.  Professor Seeman is regarded as the creator of DNA nanotechnology and was awarded the Kavli Prize in Nanoscience on June 4th, 2010.

Continue reading

No Need for Intent to Decieve: Failure to Disclose Should Automatically Render a Patent Unenforceable

Jake Meyer by Jake Meyer

The U.S. Patent System provides incentives for inventors to disclose their inventions in exchange for a limited monopoly, but patent applicants do not always disclose all of the information necessary for an accurate assessment by the U.S. Patent and Trademark Office (USPTO) of whether the patent applicant is deserving of a limited monopoly.  The Federal Circuit (the court that hears all patent appeal cases) currently has an opportunity to insure more complete information is presented to the USPTO when determining whether it should grant a particular patent.

In order for an inventor to obtain a patent, 1) an invention must be useful – the invention must have a beneficial purpose; 2) an invention must be novel – it must be new and have not been previously described to the public elsewhere; and 3) an invention must be non-obvious – the invention must not be a combination of known components or techniques that would be obvious for a person skilled in that area of technology to try together.  When applying for a patent, the applicant must disclose to the USPTO any information related to the invention and relevant to the questions of whether the invention is novel, or whether the invention is obvious.  The applicant must include relevant articles, books, patents, and other materials describing the invention (all of which is known as prior art) in the patent application.

Continue reading

The Creation of a Synthetic Cell Opens New Possibilities and Perhaps New Dangers

Jake Meyer by Jake Meyer

The biotechnology age has progressed at a rapid pace.  Every few years a new discovery in biotechnology leaves us wondering about new possibilities.  In 1997, Dolly the sheep was the first successfully cloned animalIn 2000, the Human Genome Project announced that it had assembled the first working draft of the human genomeAnd now in 2010 a team of researchers has created the first synthetic cell.  But sometimes lost with an eye-opening discovery is the story of Frankenstein and the question posed by Mary Shelley’s novel: How much tinkering should we do?  Or, updated for the 21st century, how should we regulate our new tinkering?

May 20, 2010, Researchers at the Craig Venter Institute created the first self-replicating synthetic bacterial cell.  A synthetic genome, 1.08 million base pairs long was designed by a computer, chemically made in a laboratory, and placed within a bacterium cell.  Through replication of the cell the original genome is lost and only the synthetic genome remains resulting in a new self-replicating cell controlled by the synthetic genome.  The discovery opens the possibility of engineering microbes that produce useful substances, such as vaccines and biofuels.  One possible use of this technology that is being explored is to construct genomes of photosynthetic bacteria to use light energy to produce hydrogen gas from water, which can be used as a fuel source. 

Continue reading

Rebecca Skloot’s Journey into the Life of Henrietta Lacks

Lori Andrews by Lori Andrews

In 1890 a man sold the rights to his body after death to the Royal Caroline Institute in Sweden for research purposes.  Later, he tried to return the money and cancel the contract.  In the subsequent lawsuit, the court held that he must turn his body over to the Institute and also ordered him to pay damages for diminishing the worth of his body by having two teeth removed.

Photo of Lori Andrews and Rebecca Skloot

Lori and Rebecca Skloot

Today, it would be an anathema for a person’s body to be used against his wishes or for a research subject not to be allowed to withdraw from a study.  In fact, the Uniform Anatomical Gift Act allows people to change their minds and withdraw a previous agreement to donate organs and tissue after their death and the Federal research regulations allow people to withdraw from studies without penalty or loss of benefits.  Yet the law is murky regarding research on a person’s tissue outside of his body and some modern doctors and researchers emulate the Royal Carolina Institute and stake their claims on materials from people’s bodies.

In 1951, a 31-year-old African-American woman, Henrietta Lacks, died of ovarian cancer.  Without the knowledge or consent of Lacks or her family, her tissue was taken and made into a cell line that has been extremely valuable for research and is still sold today.  In an interview in 1994, her husband said, “As far as them selling my wife’s cells without my knowledge and making a profit — I do not like that at all.  They are exploiting both of us.”
Body Bazaar Cover Image
Dorothy Nelkin and I wrote about Henrietta in our 2000 book, Body Bazaar: The Market for Human Tissue in the Biotechnology Age.  Over the past decade, journalist Rebecca Skloot probed more deeply.  In The Immortal Life of Henrietta Lacks, Skloot tells a moving story of how the unauthorized use of Henrietta’s cells (known to scientists as HeLa cells) provided the foundation for most modern medical discoveries.  I caught up with Rebecca Skloot on her whirlwind book tour when she spoke at the Northwestern Medical School.

Skloot-Book-CoverShe described how Henrietta’s cells formed the basis for much of the scientific enterprise across the world in the decades since her death.  Virtually every high school biology student, every medical student, and every vaccine maker has manipulated her cells.  While fortunes have been made on the foundation of the HeLa cells, her own children lacked access to education and basic health care.  In fact, when her children were contacted decades after her death by researchers wanting their tissue, they completely misunderstood what scientists meant by research on their mother’s cells.  They visualized their mother as still alive, in a cell, being researched upon.

But they are not the only people kept in the dark about tissue research.  How many people realize that their tissue is being used today without their knowledge and consent?  Over 282 million archived and identifiable pathological specimens from more than 176 million individuals are being stored in United States repositories.  Some specimens are anonymized or coded and not identified with specific individuals; others carry patient names or codes that allow personal identification.  Virtually everyone has his or her tissue “on file.”

Expanding markets have increased the value of this tissue, and institutions — hospitals, research laboratories, and the state and federal repositories that store tissue samples — find they possess a capital resource.  Medical centers have deals in place with biotech companies to do genetic research on their hospital patients’ tissue without the patients’ permission.

This lackadaisical approach to consent has recently been called in question.  A Native American group, the Havasupai, gave tissue to a scientist for research on diabetes.  Instead, the scientist undertook research about schizophrenia and in-breeding, which stigmatized the Havasupai, and research about geographical origins, which conflicted with the Havasupai’s religious beliefs.

When the researcher was challenged in federal court, the judge found that the Havasupai had asserted valid claims for intentional infliction of emotional distress, negligent infliction of emotional distress, civil rights violations, negligence and gross negligence.  In April 2010, the researcher’s university settled with the Havasupai, paying $700,000 to 41 members of the tribe for using their tissue without appropriate informed consent.

The attention being paid to Skloot’s excellent book and the good news of a settlement in the Havasupai case are spurring societal discussion about the use of tissue samples.  Clear laws and regulations are needed to assure that no one’s tissue is used without specific informed consent.

The specifics of Henrietta Lacks saga will soon be made into a movie, with Oprah as an executive producer.  But her story affects us all.  Hospitals, universities, research centers, and private depositories retain pathology samples and genetic data collected in the course of surgical procedures or research projects — a fact unknown to most patients.  New laws are needed to make sure we are not a nation of guinea pigs.

Should Payments to Egg Donors Be Limited?

Jake Meyer by Jake Meyer

The New York Times published a May 10, 2010 article about payments to women who donate their eggs titled “Payment Offers to Egg Donors Prompt Scrutiny,” and also asked the question of The New York Times readers Should Egg Donors Be Paid?  The process of donating eggs is time consuming, involves discomfort, and carries some physical risks to the donor, so do you compensate the donor?  Donation can cause abdominal swelling, mood swings, hot flashes and ovarian hyperstimulation syndrome, which can cause bloating, abdominal pain, and in some cases, blood clots, kidney failure, and other life-threatening ailments.  And if you do compensate an egg donor, how much do you pay an egg donor? 

The current practice in the U.S. is to allow egg donors to be paid.  The American Society for Reproductive Medicine has set guidelines for payments to egg donors.  The guidelines require justifications for payments over $5,000 and set a maximum compensation at $10,000 and also do not allow for the higher payments for specific traits.  However, advertisers are ignoring these guidelines.

A study by Dr. Aaron Levine at the Georgia Institute of Technology found that out of a sampling of 100 ads from 63 different college campuses, over a quarter of those ads exceeded the $10,000 maximum compensation guidelines set by the American Society for Reproductive Medicine.  The ads also offered higher average payments at schools with higher average SAT scores – ads averaged $2000 more for every 100 point difference in the average SAT scores.  Ads in the newspapers at Yale, Princeton, and Harvard offered $35,000 and an ad in the newspaper at Brown offered $50,000.

Are these guidelines necessary?  Should couples looking to reproduce be allowed to pay whatever price they wish for a donor egg?  Critics fear that young women will see the amount of money offered for egg donation and may overlook or not understand the potential physical and psychological risks.  Should the offers for donated eggs allowed to be higher for specific attributes?  Is an offer asking to pay $50,000 for the eggs of a donor who is tall, athletic, Ivy League educated, and with a score of at least 1400 of 1600 on the SAT appropriate?  Or are offers like this more akin to eugenics, where couples using donated eggs to conceive are paying higher premiums and selectively breeding certain traits.  The ASRM guidelines seem reasonable when the risks that an egg donor undertakes are weighed against the concern that women will donate against their best interests because of a large pay day.  Setting a limit on what an egg donor can be paid allows for an egg donor to be adequately compensated, and also addresses the issue eugenics-like trait selection.  Efforts should be made to ensure that these guidelines are more strictly followed.

Nano Ice Cream – Rich Texture, Low in Fat, and High in Unknown Risk

Jake Meyer by Jake Meyer>

At ISLAT we’ve done studies on the legal issues surrounding nanotechnology for both the Department of Energy and the National Science Foundation, but the issue of nanotechnology has not reached the general public so it is refreshing to see an in depth analysis as part of an AOL News Special Report.  The AOL News Special Report is a three part series written by Andrew Schneider that explores the health risks nanotechnology introduce and the current regulatory efforts to protect workers, consumers, and the environment from these risks.

The first article in the series is titled “Amid Nanotech’s Dazzling Promise, Health Risks Grow.”  This title is apt for the entire series as the issues that are continually raised are the great possibilities that nanotechnology promises weighed against the health risks nanotechnology contains.  The worry is that too much regulation of nanotechnology will impede the development of amazing new technologies (along with it the economic boost new technologies provide).  But too little regulation might lead to widespread harm.

The article describes some of the nanotechnology products, such as the creation of nano-sized delivery systems that can be injected into the body to seek out cancer cells and deliver cancer-fighting drugs.  I previously wrote about other medical innovations that nanotechnology could enable such as nano robots that clean arteries of cholesterol and biosensors that allow a person with diabetes to monitor their glucose level without using a lancet.  Carbon nanotubes are stronger than steel and lightweight.  I previously wrote a blog about how carbon nanotubes could be the answer for the creation of space elevators.

Continue reading

Guilt by Association: Familial DNA Searching Implicates Many On the Quest to Find The One

JenAckerby Jen Acker

When DNA is left behind at a crime scene, investigators usually run the sample through a DNA database.  All states collect DNA samples from convicted felons, and some even collect DNA from suspects brought into custody.  If the DNA found at the crime scene matches a sample in the database, a suspect has likely been identified.  Sometimes, an exact match may not be found, but a very close match may exist:  this is the essence of familial DNA searching.  These near-matches may spell trouble for the innocent relatives of people with criminal histories. 

Individuals related by blood have similarities in genetic material.  Therefore, the stored DNA of a man who has a criminal record could be used to identify his brother who does not have a criminal record.  Similarly, DNA taken from children born out of a rape has been used to identify their father, the rapist.  In at least one high profile case, familial DNA searching was used to free an innocent man who spent 19 years behind bars.

Despite the potential for identifying suspects, familial searching is not without debate, and its legality has not been vetted in the courts.  Critics contend that familial DNA searching raises concerns regarding privacy and illegal search and seizure.  While DNA near-matches indicate that a relative of a convicted criminal is likely implicated, near-matches do not indicate precisely which relative.  The fear is that family members become guilty by DNA association even when law enforcement has no other evidence to support the connection.

Continue reading

Illinois Care of Students with Diabetes Act

SarahBlennerBy Sarah Blenner, JD, MPH

One out of every 400-600 school aged children has type-1 diabetes.  Diabetes is a condition where individuals either cannot naturally produce or cannot properly use insulin.  While the medical complications and threats of low blood sugar levels are often more immediate and apparent then complications and threats of high blood sugar levels, both conditions must be treated immediately to ensure the overall safety and well being of a child with diabetes.  Keeping blood glucose levels as close to normal now will help a child live a longer, healthier life.  Since children spend a large amount of time in school, it is important for these children to control blood glucose levels during school hours.

Healthy People 2010, the U.S. Department of Health and Human Services’ National health objectives, sets a goal to increase the number of schools with a school nurse to student ratio of 1:750.   Healthy People 2010 and the National Association of School Nurses (NASN) also recognize that there are certain situations where more nurses are needed for a smaller student population, such as in situations where many of the students have healthcare needs that must be addressed during the school day. 

Continue reading

The Effect of NIH’s Genetic Testing Registry on Direct-to-Consumer Genetic Testing

Keith Syverson by Keith Syverson

In March 2010, the National Institutes of Health (NIH) announced that it is creating a voluntary national Genetic Testing Registry to provide easy public access to information regarding the availability and utility of genetic tests. The registry, which is slated to be available in 2011, will collect information from clinical, commercial, and research testing organizations and display it in a database geared towards physicians and patients. The announcement came almost two years after the Secretary Advisory Committee on Genetics, Health, and Society (SACGHS) published recommendations suggesting that the NIH establish a web-based registry for laboratory genetic tests. Ideally the registry will include information about the analytical validity, clinical validity, and the clinical utility of genetic tests. This information is particularly important for consumers who wish to utilize direct-to-consumer (DTC) genetic testing options such as 23andMe or Navigenics. Although the database is a step in the right direction for ensuring that patients and doctors receive accurate information regarding genetic testing, the registry may not alleviate the problems associated with direct-to-consumer genetic testing.

Continue reading

R.I.P. — Gene Patents and the Biotech Industry

Lori Andrews by Lori Andrews

Last Sunday’s 60 Minutes explained the logic behind a federal court decision invalidating patent claims related to the breast cancer genes.  A proponent of gene patents told 60 Minutes that patents were necessary to encourage people to find genes.  Elsewhere, interviewees have implied that invalidating gene patents will be the death knell of the biotech industry.

Lori and Morley Safer

Lori and Morley Safer

But wait a minute!  Patent law says you can only patent inventions, not products of nature.  No one invented a breast cancer gene; it exists in each of our bodies. So why do we have to pay a royalty fee for our doctor to look at any of our own genes?  It’s as if someone stole my car and then tried to lease it back to me.  If a court stopped car thieves, no one would shed a tear about the death knell of the car theft industry.

So I can’t get worked up about companies losing their gene patents.  Those companies have unjustly enriched themselves for years by claiming ownership over products of nature.  It’s as if a company patented air and charged a royalty each time we breathed.

Click here to watch the 60 Minutes interview with Lori.

Scientists were searching for and finding genes long before patents were available and there is no evidence that the grant of gene patents (as opposed to the patent on the gene sequencing machine) sped this search up. Researchers try to discover genes for a number of reasons –- to help mankind, to win a Nobel Prize, for academic advancement, and for professional status.  The fact that patents are not necessary for gene discovery and actually interfere with discovery is underscored by the fact that the professional organizations of geneticists — the people who discover genes—are the plaintiffs and amici who are urging that genes should not be patentable! In fact, in a study of American Society of Human Genetics members, 61% of those in industry, 78% of those in government, and 77% of academic scientists stated that they disapproved of patenting DNA.

Further, patents on genes actually stifle innovation. Once a gene sequence is patented, the holder of the patent can stop research by anyone else.   If a researcher wanted to study asthma, he or she would have to get permission from the holders of the patents on nine genes related to asthma.  If even one of them decided to exert exclusive control of the gene, research on cures and treatments would be stymied.  When a non-profit foundation and the American Neurological Association wanted to finance research to find a cure for a particular genetic disease, researchers were unwilling to undertake the work because of the potential for legal action against them by the holder of the patent.

Many scientists in the US ignore gene patents and do research anyway.  But they are in for a rude awakening.  Unlike in most European countries and Japan, there is no general research exception in the U.S.  So they can later be sued by the patent holder for past royalties in their use of the gene in research.  Or, more importantly, the patent holder can wait until the subsequent researcher discovers something useful, such as a gene therapy using the gene and then assert ownership over it.  Researchers who are aware of the scope of gene patents thus have no incentive to develop a true invention, such as a therapy which makes use of the gene.

The barriers to research caused by patents are even greater in genetics than in other areas of science.  In a study by the American Association for the Advancement of Science, 35% of scientific researchers had difficulty related to being allowed to use a patented invention.  The number was even higher – 76% – for bioscience researchers.  As a result, 58% of scientific researchers responded that they delayed their research, 50% responded that they changed their research, and 28% reported abandoning their research.

One study found that 53% of genetics labs have stopped doing research due to concerns about gene patents.  Another found that 49% of American Society of Human Genetics members have had to limit their research due to gene patents.  Moreover, once a patent is granted in the area of biotechnology, there is a chill on future research using the patented information, including a statistically significant decline in scientific publications using the patented information.

The invalidation of gene patents will be an overall boon to the biotech industry.  While it might threaten companies whose sole asset is an improperly-granted patent on a gene, the liberation of genes will help biotech companies who provide chip technology to test multiple genes at the same time.  The widespread availability of gene sequence information will also reward biotech companies who use that information to create better diagnostic technologies and treatments.

Justice Breyer of the U.S. Supreme Court discussed the reason why it is important not to have patents on products of nature or laws of nature.  He said:

The justification for the principle does not lie in any claim that “laws of nature” are obvious, or that their discovery is easy, or that they are not useful. To the contrary, research into such matters may be costly and time-consuming; monetary incentives may matter; and the fruits of those incentives and that research may prove of great benefit to the human race. Rather, the reason for the exclusion is that sometimes too much patent protection can impede rather than “promote the Progress of Science and useful Arts,” the constitutional objective of patent and copyright protection.

Gene patents are dead.  May they rest in peace.